One of our clinical trials showed that combination of PD‐1 inhibitor with lenvatinib as conversion therapy could benefit unresectable advanced HCC patients to achieve curative surgery, with a specific conversion rate of 30.6%.20 This evidence concerns the gene PDCD1 and hepatocellular carcinoma.